Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECIDER-2 trial of decitabine + venetoclax with all-trans retinoic acid versus placebo in induction-ineligible AML
2023-507461-26-00Phase 3Authorised
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Decitabine + venetoclax + tretinoin with Decitabine + venetoclax + placebo (2 arms). Primary endpoint: Overall survival. Planned start Sep 2022; status: authorised.
02
Drugs
tretinoindecitabinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-507461-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507461-26-00.